Britain and America have secured a key bilateral deal that will maintain zero levies on British pharmaceutical shipments going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise spending on medicines through the NHS. This commitment secures that tariffs on these key goods will remain at nothing for a timeframe of three years.
This agreement comes after earlier statements to significantly raise import taxes on branded drug imports, with increases mentioned up to double the cost.
"This arrangement between the Britain strengthens the global environment for cutting-edge drugs and brings long-overdue fairness to American-British medicine commerce," a release said.
Commercial Significance
Pharmaceuticals constitute one of the the United Kingdom's most significant exports to the America, which is easily the biggest destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of the third quarter, the UK shipped medicines valued at billions to the US. This value represented a significant portion of all goods exports in that period.
"This agreement secures jobs, increases capital expenditure and paves the way for the UK to emerge as a international leader for life sciences," a minister stated.
Specific UK Commitments
The agreement entails several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. In the past, repayments topped 20%.
Broader Context
The pact follows a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were heightened by arguments that US patients were charged several times more for the identical medicines than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or cancelled, while major investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.
